A Phase 2 interventional study of Emraclidine 30 mg in Schizophrenia, sponsored by AbbVie. Terminated at 85 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Schizophrenia by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Schizophrenia · AbbVie.
Among the 27 studies in Schizophrenia by AbbVie, this one is the 4th largest by enrollment, is one of 5 that started in 2022, is one of 13 in phase 2, and was the 26th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →1 of the 27 studies in Schizophrenia by AbbVie is open now, in 1 country. Recruiting first, the newest first:
AbbVie · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 698 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 268 across the 27 interventional studies. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 27 studies in Schizophrenia by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to assess the long-term safety and tolerability of oral emraclidine in adult participants with schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Current diagnosis other than schizophrenia (note: anxiety symptoms secondary to schizophrenia are allowed.
Any of the following:
Note: female participants who are pregnant, breastfeeding, or planning to become pregnant during IMP treatment or within 7 days after the last dose of the IMP are also excluded.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who completed treatment with emraclidine in one of the double-blind, placebo-controlled Phase 2 efficacy trials (CVL-231-2001; NCT05227690 or CVL-231-2002; NCT05227703) were denoted as "active rollover" participants. They received emraclidine 30 mg tablets orally once daily (QD) for 52 weeks in this study.
Drug: Emraclidine 30 mg
Participants who completed treatment with placebo for emraclidine in one of the double-blind, placebo-controlled Phase 2 efficacy trials (CVL-231-2001; NCT05227690 or CVL-231-2002; NCT05227703) were denoted as "placebo rollover" participants. They received emraclidine 30 mg tablets orally once daily (QD) for 52 weeks in this study.
Drug: Emraclidine 30 mg
Participants with stable schizophrenia who were not enrolled in one of the prior Phase 2 efficacy trials were denoted as "de novo" participants. They received emraclidine 30 mg tablets orally once daily (QD) for 52 weeks in this study.
Drug: Emraclidine 30 mg
Emraclidine 30 mg, oral (tablet), once per day for 52 weeks
Also known as: CVL-231, ABBV-1231
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
Time frame: From first dose of study drug until 28 days following last dose of study drug (up to Week 56)
Number of Participants With Out-of-Range Vital Signs Occurring Post-Baseline
Vital signs were obtained after the participant had been supine and at rest for 3 minutes and included systolic and diastolic blood pressure, heart rate, temperature, and respiratory rate.
Time frame: Baseline; from first dose of study drug up to Week 52
Number of Participants With Clinically Significant Changes in Body Weight
Participants' body weights were measured and recorded.
Time frame: Baseline; from first dose of study drug up to Week 52
Number of Participants With Post-Baseline Clinically Significant Physical Examinations and Neurological Examinations
The number of participants with clinically significant changes in physical and neurological examination results post-treatment was documented.
Time frame: Baseline; from first dose of study drug up to Week 52
Number of Participants With Clinically Significant Post-Baseline Changes in Electrocardiogram (ECG) Values
12-lead electrocardiogram (ECG) recordings were obtained after the participant had been supine and at rest for at least 3 minutes.
Time frame: Baseline; from first dose of study drug up to Week 52
Number of Participants With Clinically Significant Changes in Clinical Laboratory Values
Clinical laboratory tests were performed at scheduled study visits, and the investigator recorded any clinically significant changes.
Time frame: Baseline; from first dose of study drug up to Week 52
Number of Participants With Clinically Significant Changes in Metabolic Parameter Values
Clinical laboratory tests were performed at scheduled study visits, and the investigator recorded any clinically significant changes in metabolic parameter values.
Time frame: Baseline; from first dose of study drug up to Week 52
Number of Participants With Suicide-Related Treatment-Emergent Events Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).
Time frame: Baseline; from first dose of study drug up to Week 52
Change From Baseline in Simpson Angus Scale (SAS) Total Score
The SAS consists of a list of 10 symptoms of parkinsonism. Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms and a score of 4 representing a severe condition. The SAS total score is the sum of the scores for all 10 items. Baseline was defined as the last value obtained prior to initiation of study drug. Change from baseline for a given endpoint was defined as the value on a given Study Day (Time Point) minus the Baseline Value. Negative changes from Baseline indicate an improvement in symptoms.
Time frame: Baseline; Weeks 4, 8, 12, 20, 26, 32, 38, 44, and 52
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Movement Rating Score
The Abnormal Involuntary Movement Scale assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1-4), extremity movements (items 5 and 6), and trunk movements (item 7) are observed unobtrusively while the participant is at rest, and the investigator also makes global judgments on the participant's dyskinesias (items 8-10). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, awareness, severe distress). In addition, the AIMS includes 2 yes/no questions that address the participant's dental status. The AIMS Movement Rating Score is defined as the sum of individual scores from items 1-7, ranging from 0 to 28. A lower score indicates less severe or absent abnormal movements. A negative change in the mean from Baseline indicates improvement in the severity of abnormal involuntary movements.
Time frame: Baseline; Weeks 4, 8, 12, 20, 26, 32, 38, 44, and 52
Change From Baseline in Barnes Akathisia Rating Scale (BARS) Global Clinical Evaluation Score
The BARS consists of 4 items related to akathisia. The fourth item, reported here, is the Global Clinical Evaluation Score. The Global Clinical Evaluation Score is evaluated using a 6-point scale, ranging from 0 to 5, with 0 representing absence of symptoms and a score of 5 representing severe akathisia. A negative change from baseline indicates an improvement in symptoms.
Time frame: Baseline; Weeks 4, 8, 12, 20, 26, 32, 38, 44, and 52
Two groups of participants were included in the study: rollover (who completed treatment in the double-blind, placebo-controlled, Phase 2 efficacy Study CVL-231-2001 or Study CVL-231-2002) and de novo participants (who had stable schizophrenia and were not enrolled in either Phase 2 efficacy study). The study included an up to 15-day Screening Period (de novo participants only), a 52-week Treatment Period, and a 28-day Follow-up Period.
| Milestone | CVL-231-2001/2002 Active Rollover | CVL-231-2001/2002 Placebo Rollover | De Novo |
|---|---|---|---|
| Started | 97 | 49 | 552 |
| Completed | 25 | 19 | 126 |
| Not completed | 72 | 30 | 426 |
| Withdrew: Adverse event | 8 | 2 | 45 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 15 | 6 | 40 |
| Withdrew: Failure to meet continuation criteria | 0 | 0 | 3 |
| Withdrew: Lack of efficacy | 2 | 1 | 3 |
| Withdrew: Non-compliance with study schedule | 0 | 1 | 3 |
| Withdrew: Non-compliance with study drug | 7 | 0 | 16 |
| Withdrew: Physician decision | 4 | 0 | 12 |
| Withdrew: Study terminated by sponsor | 4 | 4 | 200 |
| Withdrew: Withdrawal of consent | 30 | 14 | 96 |
| Withdrew: Other, not specified | 2 | 2 | 7 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
| number of participants | CVL-231-2001/2002 Active Rollover | CVL-231-2001/2002 Placebo Rollover | De Novo |
|---|---|---|---|
| Any TEAE | 34 | 21 | 316 |
| TESAE | 7 | 2 | 35 |
Vital signs were obtained after the participant had been supine and at rest for 3 minutes and included systolic and diastolic blood pressure, heart rate, temperature, and respiratory rate.
| Participants | CVL-231-2001/2002 Active Rollover | CVL-231-2001/2002 Placebo Rollover | De Novo |
|---|---|---|---|
| Supine Systolic Blood Pressure < 90 mmHg | 0 | 0 | 1 |
| Supine Systolic Blood Pressure 140 - 160 mmHg | 8 | 2 | 34 |
| Supine Systolic Blood Pressure 160 - 200 mmHg | 1 | 0 | 5 |
| Orthostatic Change in Systolic Blood Pressure ≥ 20 mmHg decrease | 1 | 0 | 10 |
| Supine Diastolic Blood Pressure 90 - 100 mmHg | 9 | 4 | 39 |
| Supine Diastolic Blood Pressure 100 - 120 mmHg | 0 | 0 | 6 |
| Orthostatic Change in Diastolic Blood Pressure ≥ 10 mmHg decrease | 6 | 2 | 22 |
| Supine Heart Rate < 50 bpm | 2 | 0 | 6 |
| Supine Heart Rate 50 - 60 bpm | 14 | 4 | 100 |
| Supine Heart Rate 100 - 120 bpm | 1 | 1 | 21 |
| Supine Heart Rate > 120 bpm | 0 | 0 | 1 |
| Temperature < 36 °C | 1 | 1 | 9 |
| Respiratory Rate < 12 breaths/min | 1 | 1 | 1 |
| Respiratory Rate > 20 breaths/min | 0 | 1 | 2 |
Participants' body weights were measured and recorded.
| Participants | CVL-231-2001/2002 Active Rollover | CVL-231-2001/2002 Placebo Rollover | De Novo |
|---|---|---|---|
| ≥ 7% decrease | 18 | 9 | 65 |
| ≥ 7% increase | 5 | 5 | 47 |
The number of participants with clinically significant changes in physical and neurological examination results post-treatment was documented.
| Participants | CVL-231-2001/2002 Active Rollover | CVL-231-2001/2002 Placebo Rollover | De Novo |
|---|---|---|---|
| Any clinically significant physical examination findings | 2 | 1 | 4 |
| Any clinically significant neurological examination findings | 1 | 0 | 8 |
12-lead electrocardiogram (ECG) recordings were obtained after the participant had been supine and at rest for at least 3 minutes.
| Participants | CVL-231-2001/2002 Active Rollover | CVL-231-2001/2002 Placebo Rollover | De Novo |
|---|---|---|---|
| QTcF value > 450 - 480 msec | 7 | 2 | 23 |
| QTcF value > 480 - 500 msec | 1 | 0 | 1 |
| QTcF increase from Baseline > 30 - 60 msec | 20 | 10 | 70 |
| QTcF increase from Baseline > 60 msec | 1 | 0 | 0 |
Clinical laboratory tests were performed at scheduled study visits, and the investigator recorded any clinically significant changes.
| Participants | CVL-231-2001/2002 Active Rollover | CVL-231-2001/2002 Placebo Rollover | De Novo |
|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Clinical Laboratory Values | 5 | 1 | 35 |
Clinical laboratory tests were performed at scheduled study visits, and the investigator recorded any clinically significant changes in metabolic parameter values.
| Participants | CVL-231-2001/2002 Active Rollover | CVL-231-2001/2002 Placebo Rollover | De Novo |
|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Metabolic Parameter Values | 2 | 1 | 8 |
The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).
| Participants | CVL-231-2001/2002 Active Rollover | CVL-231-2001/2002 Placebo Rollover | De Novo |
|---|---|---|---|
| Treatment-Emergent Suicidal Ideation Compared to Recent History | 0 | 2 | 13 |
| Treatment-Emergent Serious Suicidal Ideation Compared to Recent History | 0 | 1 | 3 |
| Emergence of Serious Suicidal Ideation Compared to Recent History | 0 | 0 | 3 |
| Emergence of Suicidal Behavior Compared to all Prior History | 0 | 0 | 1 |
The SAS consists of a list of 10 symptoms of parkinsonism. Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms and a score of 4 representing a severe condition. The SAS total score is the sum of the scores for all 10 items. Baseline was defined as the last value obtained prior to initiation of study drug. Change from baseline for a given endpoint was defined as the value on a given Study Day (Time Point) minus the Baseline Value. Negative changes from Baseline indicate an improvement in symptoms.
| units on a scale | CVL-231-2001/2002 Active Rollover | CVL-231-2001/2002 Placebo Rollover | De Novo |
|---|---|---|---|
| Week 4 | -0.1 ± 0.46 | -0.2 ± 0.87 | 0.0 ± 0.46 |
| Week 8 | 0.0 ± 0.53 | -0.2 ± 0.91 | 0.0 ± 0.36 |
| Week 12 | -0.1 ± 0.45 | -0.2 ± 0.92 | 0.0 ± 0.42 |
| Week 20 | -0.1 ± 0.69 | -0.2 ± 1.02 | 0.0 ± 0.44 |
| Week 26 | -0.1 ± 0.63 | -0.2 ± 0.99 | 0.0 ± 0.55 |
| Week 32 | -0.2 ± 0.56 | -0.2 ± 1.03 | 0.0 ± 0.43 |
| Week 38 | -0.2 ± 0.63 | -0.3 ± 1.04 | 0.0 ± 0.41 |
| Week 44 | -0.2 ± 0.59 | 0.0 ± 1.60 | 0.0 ± 0.42 |
| Week 52 | 0.0 ± 0.29 | -0.3 ± 1.15 | 0.0 ± 0.48 |
The Abnormal Involuntary Movement Scale assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1-4), extremity movements (items 5 and 6), and trunk movements (item 7) are observed unobtrusively while the participant is at rest, and the investigator also makes global judgments on the participant's dyskinesias (items 8-10). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, awareness, severe distress). In addition, the AIMS includes 2 yes/no questions that address the participant's dental status. The AIMS Movement Rating Score is defined as the sum of individual scores from items 1-7, ranging from 0 to 28. A lower score indicates less severe or absent abnormal movements. A negative change in the mean from Baseline indicates improvement in the severity of abnormal involuntary movements.
| units on a scale | CVL-231-2001/2002 Active Rollover | CVL-231-2001/2002 Placebo Rollover | De Novo |
|---|---|---|---|
| Week 4 | 0.0 ± 0.23 | -0.1 ± 0.36 | 0.0 ± 0.58 |
| Week 8 | 0.0 ± 0.41 | 0.0 ± 0.00 | 0.0 ± 0.56 |
| Week 12 | 0.0 ± 0.13 | 0.0 ± 0.00 | 0.0 ± 0.55 |
| Week 20 | 0.0 ± 0.15 | 0.1 ± 0.59 | 0.0 ± 0.49 |
| Week 26 | 0.0 ± 0.15 | 0.0 ± 0.19 | 0.0 ± 0.68 |
| Week 32 | -0.1 ± 0.32 | 0.0 ± 0.00 | 0.0 ± 0.61 |
| Week 38 | 0.1 ± 0.53 | 0.0 ± 0.00 | 0.0 ± 0.68 |
| Week 44 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.48 |
| Week 52 | 0.0 ± 0.20 | 0.1 ± 0.46 | 0.0 ± 0.58 |
The BARS consists of 4 items related to akathisia. The fourth item, reported here, is the Global Clinical Evaluation Score. The Global Clinical Evaluation Score is evaluated using a 6-point scale, ranging from 0 to 5, with 0 representing absence of symptoms and a score of 5 representing severe akathisia. A negative change from baseline indicates an improvement in symptoms.
| units on a scale | CVL-231-2001/2002 Active Rollover | CVL-231-2001/2002 Placebo Rollover | De Novo |
|---|---|---|---|
| Week 4 | 0.0 ± 0.20 | 0.0 ± 0.37 | 0.0 ± 0.22 |
| Week 8 | 0.0 ± 0.17 | 0.0 ± 0.00 | 0.0 ± 0.17 |
| Week 12 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.22 |
| Week 20 | 0.0 ± 0.15 | 0.1 ± 0.38 | 0.0 ± 0.21 |
| Week 26 | 0.0 ± 0.15 | 0.0 ± 0.19 | 0.0 ± 0.32 |
| Week 32 | 0.0 ± 0.16 | 0.0 ± 0.00 | 0.0 ± 0.23 |
| Week 38 | 0.0 ± 0.18 | 0.0 ± 0.00 | 0.0 ± 0.21 |
| Week 44 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.15 |
| Week 52 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.17 |
Collected over All-cause mortality and adverse events reported from time informed consent was signed to end of the study. Median follow-up was 154 days for the CVL-231-2001/2002 Active Rollover group, 267 days for the CVL-231-2001/2002 Placebo Rollover group, and 213.5 days for the De Novo group.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CVL-231-2001/2002 Active Rollover | 1/97 (1%) | 7/97 (7.2%) | 24/97 (24.7%) |
| CVL-231-2001/2002 Placebo Rollover | 0/49 (0%) | 2/49 (4.1%) | 21/49 (42.9%) |
| De Novo | 2/552 (0.4%) | 35/552 (6.3%) | 212/552 (38.4%) |
| Event | CVL-231-2001/2002 Active Rollover | CVL-231-2001/2002 Placebo Rollover | De Novo |
|---|---|---|---|
| SCHIZOPHRENIAPsychiatric disorders | 3/97 | 0/49 | 22/552 |
| SYNCOPENervous system disorders | 0/97 | 1/49 | 0/552 |
| PSYCHOTIC DISORDERPsychiatric disorders | 1/97 | 1/49 | 1/552 |
| OVERDOSEInjury, poisoning and procedural complications | 1/97 | 0/49 | 0/552 |
| TIBIA FRACTUREInjury, poisoning and procedural complications | 1/97 | 0/49 | 0/552 |
| RHABDOMYOLYSISMusculoskeletal and connective tissue disorders | 1/97 | 0/49 | 0/552 |
| SCHIZOAFFECTIVE DISORDERPsychiatric disorders | 1/97 | 0/49 | 0/552 |
| ACUTE KIDNEY INJURYRenal and urinary disorders | 1/97 | 0/49 | 0/552 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 1/97 | 0/49 | 1/552 |
| AGITATIONPsychiatric disorders | 0/97 | 0/49 | 2/552 |
| Event | CVL-231-2001/2002 Active Rollover | CVL-231-2001/2002 Placebo Rollover | De Novo |
|---|---|---|---|
| HEADACHENervous system disorders | 2/97 | 5/49 | 34/552 |
| SOMNOLENCENervous system disorders | 1/97 | 1/49 | 30/552 |
| DRY MOUTHGastrointestinal disorders | 0/97 | 1/49 | 29/552 |
| DIZZINESSNervous system disorders | 1/97 | 0/49 | 29/552 |
| INSOMNIAPsychiatric disorders | 1/97 | 0/49 | 29/552 |
| WEIGHT INCREASEDInvestigations | 5/97 | 2/49 | 20/552 |
| WEIGHT DECREASEDInvestigations | 4/97 | 1/49 | 15/552 |
| FALLInjury, poisoning and procedural complications | 0/97 | 2/49 | 0/552 |
| NAUSEAGastrointestinal disorders | 1/97 | 1/49 | 19/552 |
| BACK PAINMusculoskeletal and connective tissue disorders | 3/97 | 1/49 | 9/552 |
Intent-to-treat (ITT): All participants who were enrolled in the trial
| Age, Continuous(years) | CVL-231-2001/2002 Active Rollover | CVL-231-2001/2002 Placebo Rollover | De Novo | Total |
|---|---|---|---|---|
| Mean | 44.5 ± 11.44 | 45.4 ± 11.81 | 45.1 ± 12.08 | 45.0 ± 11.96 |
| Sex: Female, Male(Participants) | CVL-231-2001/2002 Active Rollover | CVL-231-2001/2002 Placebo Rollover | De Novo | Total |
|---|---|---|---|---|
| Female | 27 | 15 | 178 | 220 |
| Male | 70 | 34 | 374 | 478 |
| Ethnicity (NIH/OMB)(Participants) | CVL-231-2001/2002 Active Rollover | CVL-231-2001/2002 Placebo Rollover | De Novo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 25 | 10 | 111 | 146 |
| Not Hispanic or Latino | 70 | 39 | 440 | 549 |
| Unknown or Not Reported | 2 | 0 | 1 | 3 |
| Race (NIH/OMB)(Participants) | CVL-231-2001/2002 Active Rollover | CVL-231-2001/2002 Placebo Rollover | De Novo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 1 | 1 | 4 | 6 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 1 | 3 |
| Black or African American | 45 | 20 | 190 | 255 |
| White | 48 | 27 | 356 | 431 |
| More than one race | 0 | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2022 to primary completion in Jun 2025, 33 months.
Results were first posted in Aug 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Emraclidine